Archives multiple-sclerosis

by in
Entry Author Date Location
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” on Dec. 14 10/21/11 Boston
Allozyne Looks to Rustle Up Interest on Wall Street With Backdoor IPO 07/13/11 Seattle
Coronado Biosciences Pulls in $25.8 Million 07/06/11 New York
Allozyne Acquires Poniard Pharmaceuticals, Finds Backdoor Route to NASDAQ 06/22/11 Seattle
Biogen Idec CEO on Move Back to Cambridge: “We’re Working on It” 06/16/11 Boston
Proteostasis Nabs Partnership, $20M Investment, from Elan To Pursue Neurology Drugs 05/25/11 Boston
Biogen Gets EU Panel OK for MS Drug 05/20/11 Boston
Alkermes Acquires Elan Drug Manufacturing Unit for $960M 05/09/11 Boston
Immune Design, Developer of New Vaccines, Adds Former Elan President as New CEO 04/27/11 Seattle
Biogen Shares Jump on Good News on Revenue, Oral MS Drug 04/21/11 Boston
BG Medicine Chief Speaks on Rough IPO Climate, (Finally) Going Public 04/21/11 Boston
Acorda Issued Patent on MS Drug Following Days of Speculation 04/19/11 New York
Aveo Adds Termeer to Board, Monsanto Partners With Atlas, Biogen Drug Meets Clinical Goal, & More Boston-Area Life Sciences News 04/15/11 Boston
Acorda Stock Halted as Shares Skyrocket on Patent Speculation 04/14/11 New York
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb 04/11/11 Boston
Experience Project Launches BroadCause, Putting Social Media to Work for Charitable Causes—and the Corporations Backing Them 04/05/11 San Francisco
Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation 03/23/11 Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News 03/04/11 Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy 03/02/11 Boston
Genzyme, After Months of Holding Out, Agrees to be Sold to Sanofi-Aventis for $20.1B 02/16/11 Boston
Biogen Board OK’s 20M Share Buyback 02/14/11 Boston
Genzyme-Sanofi Deal Might Be Close, Report Says 02/01/11 Boston
Genzyme Lets Sanofi Conduct Due Diligence 01/31/11 Boston
European Panel Rejects Biogen MS Drug 01/21/11 Boston
Dendreon’s European Plan, Williams Heads East, Allozyne Passes Clinical Trial, & More Seattle-Area Life Sciences News 01/13/11 Seattle
Allozyne Passes First Clinical Trial, Dreams Big About a Once-Monthly Multiple Sclerosis Drug 01/10/11 Seattle
Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office for a Return to Big Science 01/06/11 Boston
Biogen Idec Nabs Doug Williams as R&D Head, Steve Holtzman as BD Chief To Fill Out Management Team 01/05/11 Boston
Biogen Aims to Reduce PML Risk 12/22/10 Boston
Allozyne’s Next Drug, Made to Kill Two Birds With One Stone, Being Prepped for Clinic 11/16/10 Seattle
Page 3 of 7 « previous page · next page »